🇺🇸 FDA

Company profile · Sponsor

Immix

Immix Biopharma

IMMX · NYSE biotech LOS ANGELES, CA, USA
Pipeline
3
Drugs
0
Patents
2

Quick answer

Immix (IMMX) is a biotech company. headquartered in LOS ANGELES, CA, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 2 patents to this profile..

Company facts

Ticker IMMX
Exchange NYSE
Company type biotech
Headquarters LOS ANGELES, CA, USA
SEC CIK 0001873835

Pipeline (3)

Search pipeline →

  1. IMX-110 combined with Tislelizumab

    Immix

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  2. Imx-110

    Immix

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  3. NXC-201 CAR-T

    Immix

    Light Chain (AL) Amyloidosis

    phase 2 mab active

    1 trial

Patents (2)

Search patents →

  1. US 11819571

    Micelle constructs comprising curcumin

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9833508

    Cancer therapeutics

    Expires Mon Nov 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Immix?

Immix (IMMX) is a biotech company. headquartered in LOS ANGELES, CA, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 2 patents to this profile..

What pipeline programs does Immix sponsor?

We track 3 ClinicalTrials.gov-linked programs for Immix, including IMX-110 combined with Tislelizumab and 2 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Immix company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.